A Child With COVID-19,Type 1 Diabetes,and Candida glabrata : A Case Report and Literature Review

Arastehfar A Carvalho A Nguyen MH , et al. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J Fungi (Basel). 2020;6:211. doi:10.3390/jof6040211

Posteraro B Torelli R Vella A , et al. Pan-echinocandin-resistant Candida glabrata bloodstream infection complicating COVID-19: a fatal case report. J Fungi (Basel). 2020;6:163. doi:10.3390/jof6030163

Kamrath C Mönkemöller K Biester T , et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA. 2020;324:801-804. doi:10.1001/jama.2020.13445

Rodrigues CF Rodrigues ME Henriques M. Candida sp infections in patients with diabetes mellitus. J Clin Med. 2019;8:76. doi:10.3390/jcm8010076

Gupta A Gupta A Varma A. Candida glabrata candidemia: an emerging threat in critically ill patients. Indian J Crit Care Med. 2015;19:151-154. doi:10.4103/0972-5229.152757

Gregory JM Slaughter JC Duffus SH , et al. COVID-19 severity is tripled in the diabetes community: a prospective analysis of the pandemic’s impact in type 1 and type 2 diabetes. Diabetes Care. 2021;44:526-532. doi:10.2337/dc20-2260

Reddy PK Kuchay MS Mehta Y Mishra SK. Diabetic ketoacidosis precipitated by COVID-19: a report of two cases and review of literature. Diabetes Metab Syndr. 2020;14:1459-1462. doi:10.1016/j.dsx.2020.07.050

Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044. doi:10.1016/j.molmet.2020.101044

Calvet HM Yoshikawa TT. Infections in diabetes. Infect Dis Clin North Am. 2001;15:407-421. doi:10.1016/s0891-5520(05)70153-7

Tay MZ Poh CM Rénia L MacAry PA Ng LFP . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363-374. doi:10.1038/s41577-020-0311-8

Coate KC Cha J Shrestha S , et al; HPAP Consortium. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metab. 2020;32:1028-1040.e4. doi:10.1016/j.cmet.2020.11.006

Rodriguez-Morales AJ Cardona-Ospina JA Gutiérrez-Ocampo E , et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis. 2020;34:101623. doi:10.1016/j.tmaid.2020.101623

The Lancet Diabetes Endocrinology. COVID-19 and diabetes: a co-conspiracy? Lancet Diabetes Endocrinol. 2020;8:801. doi:10.1016/S2213-8587(20)30315-6

Müller JA Groß R Conzelmann C , et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3:149-165. doi:10.1038/s42255-021-00347-1

Blot S Vandewoude K Hoste E Poelaert J Colardyn F. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs Candida glabrata. J Hosp Infect. 2001;47:308-313. doi:10.1053/jhin.2000.0918

Guimarães T Nucci M Mendonça JS , et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J Infect Dis. 2012;16:e442-e447. doi:10.1016/j.ijid.2012.02.005

Klevay MJ Horn DL Neofytos D Pfaller MA Diekema DJ ; PATH Alliance. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis. 2009;64:152-157. doi:10.1016/j.diagmicrobio.2009.03.007

Bordallo-Cardona MÁ Escribano P de la Pedrosa EG , et al. In vitro exposure to increasing micafungin concentrations easily promotes echinocandin resistance in Candida glabrata isolates. Antimicrob Agents Chemother. 2017;61:e01542-16. doi:10.1128/AAC.01542-16

Alexander BD Johnson MD Pfeiffer CD , et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724-1732. doi:10.1093/cid/cit136

Shields RK Nguyen MH Press EG Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother. 2014;58:7601-7605. doi:10.1128/AAC.04134-14

Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts: Approved Standard M60. 1st ed. Clinical and Laboratory Standards Institute; 2017.

Shields RK Kline EG Healey KR , et al. Spontaneous mutational frequency and FKS mutation rates vary by echinocandin agent against Candida glabrata. Antimicrob Agents Chemother. 2018;63:e01692-18. doi:10.1128/AAC.01692-18